Compare use cases
Drop two or three slugs into the URL — for example ?slugs=demo-mia-breast-screening,demo-idx-dr-retinopathy — or pick from the validated catalogue below.
Pick from validated:
AI imaging triage for the acute stroke pathwayAI second reader for breast cancer screeningAutonomous diabetic retinopathy screening in primary carePre-operative risk-stratification model for major surgerySelf-referral assistant for NHS Talking TherapiesType-2 diabetes long-term outcome predictor
Clear selection| Type-2 diabetes long-term outcome predictor Netherlands | AI second reader for breast cancer screening United Kingdom | |
|---|---|---|
| Trust badge | Validated | Validated |
| Evidence strength | Robust evidence | Emerging evidence |
| Pipeline stage | Validated | Validated |
| Intended use | Estimates 5-year risk of major diabetes-related complications (cardiovascular, renal, retinal) from longitudinal primary-care records to support care-plan intensification. | Acts as an independent second reader of screening mammograms to support the double-reading workflow and reduce reader workload without lowering cancer detection. |
| Specialty | Endocrinology | Radiology |
| Autonomy | Informs a human (advisory) | Informs a human (advisory) |
| Deployment | Active deployment | Active deployment |
| EU AI Act tier | High-risk | High-risk |
| EU MDR class | Not a device | Class IIb |
| CE marking | Not required | CE marked |
| NICE ESF tier | Tier C — treat / diagnose / calculate risk | Tier C — treat / diagnose / calculate risk |
| Headline metric | AUC / AUROC: 0.82 | Sensitivity: 0.91 |
| Subgroup assessed | Yes | Yes |